iShares Global 100

Most Recent

  • uploads///PEP Q EPS
    Consumer

    What Do Analysts Expect from PepsiCo’s 2Q16 Earnings?

    PepsiCo’s (PEP) performance in recent quarters has been under pressure due to currency headwinds and weakness in carbonated soft drink volumes.

    By Sirisha Bhogaraju
  • uploads///Q Asia Region
    Earnings Report

    Why Philip Morris’s 1Q16 Market Share Declined in Asia

    Net revenue for Philip Morris’s (PM) Asia region decreased 8.7% to ~$2 billion in 1Q16. This compares to $2.2 billion in 1Q15.

    By Penny Morgan
  • uploads///MSCI Performance
    Financials

    Overview: 3 things to know about currency hedging

    Your total return depends on both equity and currency returns, which are sensitive to economic, political, and market events, and fluctuate over time.

    By BlackRock
  • uploads///Chart
    Earnings Report

    Merck’s 4Q17 Estimates: Pharmaceutical Segment

    Merck & Co.’s (MRK) diabetes portfolio is expected to report a decline in operating revenues in 4Q17 due to lower sales of Janumet.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Johnson & Johnson’s Growth Rate for 4Q17

    Johnson & Johnson (JNJ) reported 11.5% growth in its revenues to ~$20.2 billion during 4Q17, compared to ~$18.1 billion during 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyst Ratings and Recommendations for Johnson & Johnson

    JNJ stock has risen 27.9% in the last 12 months. Analysts estimate that the stock could rise 1.4% over the next 12 months.

    By Mike Benson
  • uploads///Chart  Rev Brkup
    Company & Industry Overviews

    Behind Pfizer’s Business Segments in 1Q17

    Pfizer’s Innovative Health segment contributes ~58% of PFE’s total revenues and reported an operational growth of 6% to $7.4 billion for 1Q17.

    By Mike Benson
  • uploads///Chart  Onco
    Company & Industry Overviews

    How AstraZeneca’s Oncology Segment Performed in 1Q17

    AstraZeneca’s (AZN) Oncology segment has consistently reported revenue growth over the last few years, and it’s one of the company’s key areas of focus.

    By Mike Benson
  • uploads///Chart  Rev EPS
    Earnings Report

    Why Novartis’s 1Q17 Revenues Missed Analysts’ Estimates

    Novartis (NVS) released its 1Q17 earnings on April 25, 2017, reporting a 25.0% rise in revenues at constant exchange rates compared to 1Q16.

    By Mike Benson
  • uploads///Chart  EPS
    Earnings Report

    What Analysts Predict for AstraZeneca’s 1Q17 Earnings

    Analysts estimate AstraZeneca will post EPS (or earnings per share) of $0.40 and revenues of $5.4 billion in 1Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Pfizer’s Valuation Compare to Peers?

    Pfizer (PFE) reported an 8% increase in revenues to $52.8 billion for 2016 as compared to $48.9 billion for 2015.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    AstraZeneca’s Other Products Segment Is Losing Market Share

    For 2016, Synagis reported 2% growth at constant exchange rates, following its 14% growth in sales in the US.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Chart in Focus: Performance of AstraZeneca’s Growth Platforms in 2016

    AstraZeneca’s (AZN) Respiratory Product sales fell 3% at constant exchange rates to ~$4.8 billion during fiscal 2016.

    By Mike Benson
  • uploads///KO volume
    Company & Industry Overviews

    Coca-Cola Keeps Its Focus on Still Beverages for Future Growth

    Coca-Cola’s (KO) still beverage volumes have seen higher growth compared to sparkling or soda beverages.

    By Sirisha Bhogaraju
  • uploads///KO Sales Q
    Consumer

    Coca-Cola’s 2Q16 Revenue Fell Due to Headwinds

    Coca-Cola generated revenue of $11.5 billion in fiscal 2Q16 ending July 1, 2016. It missed analysts’ consensus revenue estimate of $11.6 billion.

    By Sirisha Bhogaraju
  • uploads///WMT Margins
    Company & Industry Overviews

    Can Walmart Deliver Operating Margin Expansion amid Headwinds?

    In fiscal 1Q17, Walmart’s operating margin declined by about 40 basis points to 4.6% mainly due to a rise in expenses associated with the planned wage rate increase in the Walmart US and Sam’s Club segments.

    By Sirisha Bhogaraju
  • uploads///Stock Price
    Macroeconomic Analysis

    P&G’s Stock Price Reaction to the Old Spice Lawsuit

    After a lawsuit was filed against Procter & Gamble (PG), or P&G, for its Old Spice deodorant, P&G’s stock price opened with a fall of 0.4% to $82.46 on March 24, 2016.

    By Penny Morgan
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.